

Slightly technical article intended for medical professionals, which means it has lots of long words. Each section has been extensively covered in other articles on the site.

This is the full article spltd into chapters below

HANDBOOK ON ARACHNOIDITIS

INTRODUCTION:

Arachnoiditis is a chronic, insidious condition that causes debilitating, intractable pain and a range of other neurological problems. It has been regarded as rare by the medical community, but Burton reported as early as 1978([\[i\]](#)) that it is “common in patients with severe back and/or leg pain and functional impairment due to the failed back surgery syndrome.”

Adhesive arachnoiditis is not a notifiable disease and is significantly under-diagnosed.

PATHOLOGY:

Arachnoiditis is chronic inflammation of the arachnoid layer of the meninges, which consists of trabeculae, a mesh of interwoven collagen fibrils resembling tissue paper. These secrete spinal fluid, which circulates through the cerebrospinal axis and is absorbed through the arachnoid villi in the brain.

The initial phase of the inflammatory process involves influx of white blood cells in response to an insult to the subarachnoid space, such as blood (trauma, surgery), foreign substance (dye, etc) or infectious agent (e.g. meningitis). This is initiated via the action of cytokines. There is infiltration by macrophages and mesenchymal cells; the latter transform into fibroblasts, which lay down collagen.

Usually the fibrinolytic process, which breaks down excess scar tissue, limits this, but in arachnoiditis the scar tissue continues to form. Authors such as Jayson ([\[ii\]](#)) have suggested that there may be a defect in the fibrinolytic pathway.

In the first stage involves radiculitis and the adjacent blood vessel hyperaemia. The subarachnoid space disappears. Deposition of collagen fibrils begins. In the second stage, (arachnoiditis) the scar tissue increases, and the nerves become adherent to each other and the dura.

The third stage, (adhesive arachnoiditis), involves complete encapsulation of the nerve roots. The subsequent compression causes them to atrophy.

The scarring prevents the arachnoid from producing spinal fluid in that area.

Complications include: Subarachnoid cysts: These are a recognised complication of arachnoiditis, in particular that caused by myelographic dyes or epidural anaesthesia. ([\[iii\]](#)

) They tend to be more common in the thoracic region than cervical or lumbar. In symptomatic cases, clinical presentation is generally non-specific, although there may be a sensory level, unlike in uncomplicated arachnoiditis. Surgical excision or drainage is often successful, provided that there is early intervention.□□□□□□□□□□□□□□□□□□□□

Syringomyelia is an uncommon complication of arachnoiditis, probably arising due to the pressure dissociation between the subarachnoid space and the central canal. Kamada et al ([iv]) recommend follow-up serial MRI imaging for patients with adhesive arachnoiditis in order to detect syringomyelia as early as possible. It should be suspected if there is an increasing scoliosis (which is thought to be due to unequal nerve supply to the paraspinal muscles), with pain in a "cape-like" distribution in the upper body and areas of dissociated sensory loss, in particular, loss of temperature sensation in upper limbs which may lead to painless burns. There may be atrophy of small muscles in the hands and spastic paresis, gradually progressive, leading to difficulty in walking.

A further, rare, complication is communicating hydrocephalus. This is thought to be due to alterations in the cerebrospinal fluid dynamics, due to the effects of the scarring in the subarachnoid space.

1. Of mechanically-induced arachnoiditis (MIA)

Chronic disc prolapse/ degenerative disc disease

Chemonucleolysis with chymopapain

3.Miscellaneous

Subarachnoid haemorrhage

Infection e.g. meningitis

SYMPTOMATOLOGY:

In MIA, these tend to be more directly related to the pathological lesion, although there may be an element of central pain.

In CIA, there is a more florid, systemic picture, with a higher number of widespread autonomic features and often autoimmune type symptoms.

The predominant and most distressing symptom of arachnoiditis is chronic, persistent pain, which

is primarily neurogenic and thus difficult to treat.

Pain tends to increase with activity. There may be a delay after onset of activity, with a slow summation, to a point where the pain suddenly becomes unbearable and then persists once the activity has ceased. This can make it difficult for patients and physicians or physiotherapists to assess what is the tolerable level of exercise.□□□□

Pain may be due to other factors besides nerve damage. These include musculoskeletal secondary to disuse, overuse or compensatory use of muscle groups, due to alteration of spine dynamics. There may also be muscle tension due to being in pain, or spasticity caused by nerve damage. Joint pain may be due to similar factors, or may be part of the autoimmune picture (see below).

Deafferentation pain (causalgia/dysesthesia): Pain is generally described as burning, but often people are unable to describe it. It is specifically a feature of incomplete nerve damage.□ Many patients suffer from burning feet, in particular.

Lancinating pain: The majority of patients experience transient shooting pains that may vary in intensity from an insect bite to an electric shock.

There is often an element of central pain, including feeling pain from normally painless stimuli especially from light touch such as clothing (allodynia).

Changes in temperature commonly trigger this type of pain, so that sufferers have a very narrow window of comfort as regards temperature. (See also under autonomic effects).

Hyperpathia: an enhanced response to painful stimuli, suggestive of a low pain threshold. In fact, there is not a lowered threshold, rather a raised one, but once it is reached the response is magnified. This is called "delay with overshoot";. This is particularly noticeable in "visceral hyperpathia"; in which normal bladder and bowel sensation is diminished, but once the signals of fullness are perceived, there is burning pain and urgency. This can lead to embarrassing accidents, especially if there is also nerve damage to bladder or bowel causing hyperactivity or sphincter dysfunction.

In most cases: lumbar, buttocks, legs (often both), feet, perineum, hip, abdomen.

However, it is important to remember that one of the aspects of central pain is that pain may be experienced over large areas of the body, rather than just in the lower part. This may lead the patient to fear that the disease has spread.

Motor nerve damage may cause loss of muscle strength, especially in the lower back and legs, in some patients. In most cases with weakness, it is mild, but it may progress sufficiently in some patients to necessitate use of walking aids or even a wheelchair. There seems to be a phenomenon that some patients reach a plateau in their symptoms, but can then rapidly deteriorate after a minor accident, such as a fall. The reason for this is unclear.

Increase in muscle tone is quite a common feature and makes the legs stiff, which may have an effect on mobility.

A number of patients complain of symptoms suggestive of Restless Legs Syndrome, with nocturnal unpleasant sensations in the legs, accompanied by motor restlessness. Less commonly there may be trouble swallowing, sometimes due to oesophageal muscle spasms. (See also under autonomic problems).

Principal symptoms of autonomic dysfunction include:

Sexual dysfunction may affect potency and ejaculation in men, as well as causing problems with orgasm in both sexes.

)

Oedema of the limbs is seen in some patients. A number of patients seem to be

carbamazepine.) ([\[vi\]](#))

Recurrent dental problems are quite common. Many patients undergo repeated root canal procedures but continue to suffer from facial pain and odontalgia without attributable dental pathology. A number of patients also suffer from bleeding gums (periodontal disease) and a few have "burning mouth syndrome". It is possible that some of these problems are related to medications that cause dry mouth, the lack of saliva contributing to reduced protection against infection and caries. The burning mouth symptoms could have a neuropathic component.

Dysphagia may affect some patients, especially those who have cervical pathology. In particular, this may occur if there is arachnoiditis accompanied by degenerative changes such as anterior osteophytes.

However, it may also be experienced by those with only lumbar pathology, possibly as a result of oesophageal reflux (due to autonomic effects on vagal tone), which may also cause non-cardiogenic chest pain.

Pharyngeal symptoms may include feeling as if a lump is stuck in the throat, and this may be dismissed by some clinicians as "globus hystericus".

Fatigue is a very common complaint, and can be due to a variety of factors.

Weight gain is a common problem. This is largely to do with decreased mobility and possibly to fluid retention secondary to medication (from drugs such as: Amitriptyline, Gabapentin, Ibuprofen, Morphine and other opiates, prednisolone/methylprednisolone). Alternatively, some patients may suffer weight loss, due to general debility and often, poor appetite.

The cognitive effects of arachnoiditis are anxiety and reduced ability to think clearly, with some short-term memory impairment. These are usually in direct proportion to the pain level being experienced. ([\[vii\]](#))

Sleep disturbance is common, and usually directly related to pain. It may contribute to depression, which is an understandable reaction to intractable pain, loss of function, loss of role and job, financial and relationship problems as seen in other chronic, debilitating conditions.

Fear for the future (prognosis cannot be predicted) and uncertainty about the diagnosis substantially increase this problem.

Many sufferers are reluctant to admit to depression.

There are a few patients who develop liver and kidney problems, probably due to adverse effects from medication.

spectrum of the course of the disease, which varies from mild and non-progressive, to a fulminating progression that may cause paralysis and even death. Wilkinson (

[\[x\]](#)

) believes that progression after the first 24 months is unlikely to be due to the disease process alone.□□ Most authors state that its onset may be years after the precipitating cause.

In general, arachnoiditis presents a highly variable clinical picture, with a fluctuating course.

DIFFERENTIAL DIAGNOSIS

Essentially, this involves excluding other causes of FBSS, such as recurrent disc herniation, disc fragments, stenosis, spondylosis or epidural fibrosis.

However, other causes of polyneuropathy should also be considered, especially those of an autoimmune origin.

It is interesting to note that a number of patients have a dual diagnosis of arachnoiditis and Multiple Sclerosis. This is presumably due to some similarities between the two conditions.

Fibromyalgic symptoms are likely to be part of the arachnoiditis syndrome, as opposed to being due to a separate disease entity.

Limb symptoms may be diagnosed as RSD.

DIAGNOSTIC TESTS

As arachnoiditis does not present with a discrete clinical picture of specific motor, sensory and reflex abnormalities, diagnosis tends to rest on tests such as MRI or CT scans. The current investigation of choice is a T2 weighted, fat suppressed, gadolinium enhanced, high resolution MRI scan. Ideally, a neuroradiologist experienced with the appearance of arachnoiditis should read this.

It is important that treatable causes of Failed Back Surgery Syndrome (FBSS) such as recurrent disc herniation, disc fragments or stenosis be excluded.

Further tests, which demonstrate nerve damage, include EMG and nerve conduction studies.

For bladder dysfunction, urodynamic studies may be required.

TREATMENT OPTIONS

Generally speaking, this complex neurogenic pain syndrome is best treated at a specialist pain clinic, with a multidisciplinary approach.

[illegible]

□ □ □ □ □ □ □ □ □ □ □ □

Once control has been established, it is advisable to change to a slow release preparation such as MS Continus, which has a predictable duration of action for 8-12 hours, and can thus be given twice daily.

Fluctuations in dose requirement may occur, and in this case, the slow-release preparation should be replaced with a shorter acting one for the period of increased dose requirement.

Adjunctive treatment may also be necessary:

Antidepressants are useful for the background burning neuropathic pain, but are used in far lower doses than for depression (e.g. amitriptyline 25mg at night). It should be noted that the more selective antidepressants such as Prozac have been found to be poorly effective against neuropathic pain, first generation tricyclics being much more useful.

[illegible]

Anticonvulsants such as carbamazepine are particularly useful for the sharp, lancinating type of neuropathic pain. A relatively new drug, Neurontin (Gabapentin) is useful for pain relief and muscle spasms.

Antiarrrhythmic drugs such as mexiletine may also be used for neuropathic pain.

Muscle relaxants may be needed, including benzodiazepines such as diazepam.

Baclofen is a useful drug for spasticity. However, it should be noted that paradoxical increase in spasticity might occur. Also the Committee for Safety of Medicines (CSM) has advised that serious side-effects such as autonomic dysreflexia may be seen on withdrawal and a gradual dose reduction over at least 1-2 weeks should be undertaken to

avoid these. ([\[xi\]](#))

Non-steroidal anti-inflammatory drugs are not generally effective for pain relief and may cause significant gastrointestinal side effects and occasionally kidney problems after prolonged use.

Some patients have found that the troublesome nocturnal muscle cramps may be relieved by quinine.

Invasive treatments

These are not recommended by the Arachnoiditis Trust who believe that ANY invasive procedure carries a significant risk of exacerbating the inflammation of arachnoiditis, thereby worsening the patient's condition.

However, as always, it must be a question of weighing up possible benefits against possible risks, and individual needs must be assessed.

INA (Intraspinal narcotic analgesia): the "pump". This was originally developed for use in terminally ill cancer patients and thus was not being used long term. Of the studies of long term pump use, there are varying opinions as to its safety and efficacy. One recent paper states: "About

one third of the patients get good long-term pain relief without

Complications or side effects, many require the addition of local anesthetics, and some never get effective relief. There are major questions to be answered before this form of therapy becomes widely disseminated." ([\[xii\]](#))

Opiates are often supplemented with either local anaesthetics such as bupivacaine, or antispasmodics such as baclofen.

It is vital to ensure that preservative free solution is used.

Adverse effects of INA such as constipation, nausea, vomiting and itching tend to be short-term, whereas loss of libido and potency may persist for several months. The most persistent side-effects are sweating and oedema, the latter of which may necessitate INA being discontinued. The most serious adverse effect is respiratory depression

Spinal Cord Electrostimulation (SCS) involves electrical stimulation by implanted electrodes around the spinal cord, (in the epidural space), in the area that is most involved in causing pain. The very low energy current shuts down the input of pain fibres. Success rates seem to vary in different studies but are overall approximately 50% when all types

of chronic pain are considered, and the benefits may decrease with time. However, there is little literature on its efficacy in the specific case of arachnoiditis. Kumar ([\[xiii\]](#)) suggests that there is a favourable response to treatment of postsurgical arachnoiditis or perineural fibrosis if the pain is predominantly confined to one lower extremity.

Meilman et al (

[\[xiv\]](#)

[xv]

Epidural steroid and local anaesthetic injections: these are of questionable (and temporary) benefit and carry a risk of causing the very problem they are being used to treat. O'Connor et al ([\[xvi\]](#)) sum up the situation by stating that the "abnormalities of the epidural and subarachnoid spaces in such patients"(i.e. with chronic spinal arachnoiditis)... gives rise to "unpredictable and potentially dangerous results" following drug injection into these spaces.

Local nerve blocks

For those patients who have been diagnosed with RSD, sympathetic blockade may be offered. However, the literature is divided as to the efficacy of these techniques. Whilst they may be of use in the initial phases of the condition, when sympathetically maintained pain (SMP) is predominant, once central sensitization occurs (and thence what is termed "sympathetically independent pain: SIP") they are much less likely to be effective.

Other modes of administration

These include transdermal patches e.g. clonidine (but may cause hypotension) fentanyl (an opiate agonist). Fentanyl patches tend to produce fewer side effects than oral morphine.

Topical application of capsaicin is used to treat pain in peripheral neuropathies such as seen in diabetes mellitus. However, many patients find the initial (expected) increase in pain (which occurs prior to the anaesthetic effect) is intolerable, and few remain using it.

111

Non-pharmacological treatments

These include Transcutaneous Electrical Nerve Stimulation: TENS (of limited use)

Acupuncture (contact with patients who have tried this suggests that it is not as useful as could be hoped)

Physiotherapy: must be gentle as vigorous exercise may precipitate a flare-up. As in PPS, a non-fatiguing programme is likely to be the most beneficial.

Hydrotherapy: often very useful, but the water must not be too warm (heat intolerance is common in arachnoiditis patients)

Hypnosis

[ii] Jayson MI, Keegan A, Million R, Tomlinson I *Lancet* 1984 Nov 24; 2(8413): 1186-7 A fibrinolytic defect in chronic back pain syndromes.

[iii] Torres D, Bauso Toselli L, Vecchi E, Leiguarda R, Doctorovich D, Merello M, Guevara J, Nogues M *Medecina (B Aires)* 1993;53(50):391-396 [Spinal arachnoiditis as a complication of peridural anesthesia]

Sklar EM, Quencer RM, Green BA, Montalvo BM, Post MJ *Radiology* 1991 Nov;18(2):549-554 Complications of epidural anesthesia: MR appearances of abnormalities

Nogues MA, Merello M, Leiguarda R, Guevara J, Figari A *Eur Neurol* 1992;32(2):99-101 Subarachnoid and intramedullary cysts secondary to epidural anesthesia for gynecological surgery

Tseng SH, Lin SM *Clin Neurol Neurosurg* 1997 Dec; 99(4): 256-8 Surgical treatment of thoracic arachnoiditis with multiple subarachnoid cysts caused by epidural anesthesia.□

[iv] Kamada K, Iwasaki Y, Hida K, Abe H, Isu T *No Shinkei Geka* 1993 Feb;21(2):135-140 [Syringomyelia secondary to adhesive arachnoiditis: clinical profiles and efficacy of shunt operations]

[v] Mathias CJ *Hypertension* 1991 Nov; 18(5 Suppl): III22-30 Role of sympathetic efferent nerves in blood pressure regulation and in hypertension.

Colachis SC 3d *J Am Paraplegia Soc* 1992 Jul; 15(3):171-86 Autonomic hyperreflexia with spinal cord injury.

[vi] Bayer A, Thiel HJ, Zrenner E, Paulus W, Ried S, Schmidt D *Nervenarzt* 1995 Feb; 66(2): 89-96 [Disorders of color perception and increase glare sensitivity in phenytoin and carbamazepine therapy. Ocular side effects of anticonvulsants.

[vii] Luoto S, Taimela S, Hurri H, Alaranta H *Spine* 1999 Feb 1; 24(3): 255-61 Mechanisms explaining the association between low back trouble and deficits in information processing. A controlled study with follow-up.

Kuhajda MC, Thorn BE, Klinger MR *Ann Behav Med* 1998 Winter; 20(1): 31-5 The effect of pain on memory for affective words.

[\[viii\]](#) Hendler NH, Bergson C, Morrison C *Psychosomatics* 1993 Dec; 34 (6): 49-501
Overlooked Physical Diagnoses in Chronic Pain Patients Involved in Litigation, Part 2.

[\[ix\]](#) Guyer DW, Wiltse LL, Eskay ML and Guyer BH. *Spine* 1989 Dec; 14(12): 1332-1341
The long range prognosis of arachnoiditis.

[\[x\]](#) Wilkinson HA *Alternative therapies for the Failed Back Syndrome* in The Adult Spine, JW Frymoyer ed.1991

[\[xi\]](#) British National Formulary□ Number 35 (March 1998)

[\[xii\]](#) □ James A. Stangl and John D. Loeser: *Current Review of Pain* 1997 1: 353-360.
Intraspinal Opioid Infusion Therapy in the Treatment of Chronic Nonmalignant Pain
[Review article]

[\[xiii\]](#) Kumar K, Nath R, Wyant GM *J Neurosurg* 1991 Sep; 75(3): 402-7 Treatment of
chronic pain by epidural spinal cord stimulation: a 10-year experience.

[xiv] Meilman PW, Leibrock LG, Leong FT *Clin J Pain* 1989 Jun; 5(2): 189-93 Outcome of implanted spinal cord stimulation in the treatment of chronic pain: arachnoiditis versus single nerve root injury and mononeuropathy. Brief clinical note.

[xv] Ronzoni G, De Vecchis M, Rizzotto A, Raschi R, Cuneo L *Ann Urol (Paris)* 1988; 22(1): 31-4 [Long-term results of spinal cord electrostimulation in the treatment of micturition disorders associated with neurogenic bladder].

[xvi] O'Connor M, Brighthouse D, Glynn CJ *Clin J Pain* 1990 Sep; 6(3): 240-2 Unusual complications of the treatment of chronic spinal arachnoiditis.

[xvii] El-sayed A et al *JAMA* 1999; 281:818-823 Percutaneous Electrical Nerve Stimulation for Low Back Pain. A Randomised Crossover Study.